Disclaimer:

This website is intended solely for the education and information of medical professionals. It is not intended for use by patients and does not make any claims about the effectiveness of regenerative medicine or related therapies in medical treatments.

Regenerative therapies hold significant potential in addressing various health conditions, but this field is still in its early stages. This website provides information to medical professionals regarding regenerative medicine, ExoMedTech’s MSC Exosomes, and the key in vitro, animal model, and clinical research conducted across medical specialties. However, due to the evolving nature of regenerative medicine, clinical studies are currently insufficient to confirm the definitive effectiveness of these therapies.

While ExoMedTech products are manufactured in an FDA-compliant laboratory, they are not FDA-approved for treatment efficacy. The FDA has stated:

"Medical products intended to treat, cure, or prevent diseases generally require FDA approval before marketing. To date, the FDA has not approved any stem cell-based products for clinical use, except for cord blood-derived hematopoietic progenitor cells (blood-forming stem cells) for certain indications."

Patients in the U.S. who are interested in regenerative therapies should consult their physicians about the status of FDA approval for any product and/or explore participation in clinical trials. For those considering regenerative therapies outside the U.S., it is essential to review the regulations and requirements of clinical studies in the respective country, as these can vary significantly.